Pharming Group set for best day in nearly 3 yrs after FDA approves immune disorder drug
27/03/2023 08:55
** Dutch-listed shares in Pharming Group PHAR.AS jump as
much as 30% after the U.S. Food and Drug Administration (FDA)
approved the group's immune disorder drug Leniolisib
** The drug, which will be sold under the brand name Joenja,
is the first approved drug in the U.S. to treat a primary
immunodeficiency that affects about 1 to 2 people in a million
** Joenja is expected to launch in the U.S. in early April
and will be available for shipment in mid-April, the company
said
** At least two analysts expected the drug to be priced at
as much as $400,000
** The stock was up 23% by 0754 GMT and on track for its
best day since April 21, 2020
(Reporting by Federica Mileo in Gdansk)
((Federica.mileo@thomsonreuters.com))